Drug Research
New Nickel Complex Revolutionizes Pharmaceutical Synthesis
The creation of a tool that can enable organic chemical processes that were not possible before has given the pharmaceutical business new ways to make effective drugs more quickly.
In the past, most drugs were put together using alkyl building...
Drug Research
Speeding Up Toxicology Materials For Faster Drug Development
Quick delivery of toxicological materials
According to Alejandro Fernandez Martell and James Berrie from Lonza, a bottleneck has developed in the supply of toxicological data to support INDs for novel therapies and, therefore, delivery of FIH studies, as a result...
Drug Research
ArisGlobal Extends Collaboration with Sitero for Drug Development Technology Platform
ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, and Sitero LLC, a next-generation clinical trial solutions provider, today announced an expansion of their strategic partnership. This collaboration integrates Sitero's unified eClinical technology platform...
Drug Research
Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing
Recipharm announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech transfer and manufacturing. With its innovative combination and systematic application of material sciences, statistical tools...
Drug Research
Radiopharmaceuticals : Rapid Growth And Rising Investments
The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field.
Recent mergers, purchases, and joint deals...
Drug Research
GSKs Lung Cancer ADC Earns FDA Breakthrough Designation
The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year.
The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...
Drug Research
Bayer And NextRNA Partner On New Small Molecule Cancer Drugs
Bayer and NextRNA Therapeutics, a biotechnology company, announced that they would be working together to create a new type of small molecule cancer drug. The two companies agreed to a deal that could be worth over $500 million.
The two...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read